



Xtandi® (enzalutamide) – New formulation approval

- On August 4, 2020, the FDA approved Astellas' Xtandi (enzalutamide) tablets, for the treatment of patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
 - Previously, Xtandi was approved as 40 mg capsules for the same indications.
- Following a single dose administration of 160 mg enzalutamide in healthy male volunteers, enzalutamide extent of absorption (AUC) was comparable between Xtandi tablet and Xtandi capsule, but the mean C_{max} was 10%-28% lower than that of Xtandi capsules. The steady-state pharmacokinetic profiles (AUC and C_{max}) of enzalutamide and N-desmethyl enzalutamide are similar for Xtandi tablet and Xtandi capsule.
- Warnings and precautions for Xtandi include seizure, posterior reversible encephalopathy syndrome, hypersensitivity, ischemic heart disease, falls and fractures, and embryo-fetal toxicity.
- The most common adverse reactions (≥ 10% and ≥ 2% over placebo) with Xtandi use were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.
- The recommended dose of Xtandi is 160 mg (two 80 mg tablets or four 40 mg tablets or four 40 mg capsules) administered orally once daily.
 - Patients receiving Xtandi should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.
- Astellas' launch plans for Xtandi tablets are pending. Xtandi will be available as 40 mg and 80 mg tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.